Dedicated to
advancing pancreatic cancer research and providing support to patients and their families.
The Griffith Family Foundation's signature initiative is Sideline Cancer ®, which was started in 2012 by a motivated group of students to help
advance pancreatic cancer research.
Not exact matches
A clinical trial conducted by researchers at the Virginia G. Piper
Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic c
Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics
Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with
advanced, previously - treated
pancreatic cancercancer.
The current standard of care for
advanced pancreatic cancer — a combination of nab - paclitaxel and gemcitabine — was developed by TGen and the HonorHealth
Research Institute, and approved by the U.S. Food and Drug Administration in 2013.
For patients with locally
advanced pancreatic cancer, the combination of chemotherapy and stereotactic ablative radiation (SABR) may be a promising treatment option, ultimately allowing them to undergo surgery that may not otherwise be an option, according to
research presented today at the American Society for Radiation Oncology's (ASTRO's) 56th Annual Meeting.
«Based on this
research, we are now conducting a first - in - human study combining the PARP inhibitor with radiation and chemotherapy in patients with locally
advanced pancreatic cancer, with an ultimate goal of improving survival rates and treatment outcomes,» said Tuli.
«To move the needle forward toward prolonged survival and better treatment outcomes, our
research team created a combined investigational regimen for patients with locally
advanced pancreatic cancer,» said Richard Tuli, MD, PhD, a radiation oncologist in the Department of Radiation Oncology and a member of the Samuel Oschin Comprehensive Cancer Inst
cancer,» said Richard Tuli, MD, PhD, a radiation oncologist in the Department of Radiation Oncology and a member of the Samuel Oschin Comprehensive
Cancer Inst
Cancer Institute.
I have also pursued clinical and
research interests in nutrition and
cancer prevention, and the treatment of
advanced esophageal and
pancreatic cancers.
MD Anderson's Institute for Applied
Cancer Science (IACS) in combination with Deerfield will provide drug discovery and development expertise, together with translational
research focused at
advancing autophagy therapeutics into trials in melanoma, lung and
pancreatic cancers.
The
Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreat
Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic c
Cancer Action Network is a nationwide network of people dedicated to working together to
advance research, support patients and create hope for those affected by
pancreaticpancreatic cancercancer.
The Lustgarten Foundation is committed to
advancing the scientific and medical
research related to the diagnosis, treatment, cure and prevention of
pancreatic cancer.